MDT N Stock Overview Develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Medtronic plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Medtronic Historical stock prices Current Share Price US$1,800.00 52 Week High US$1,804.00 52 Week Low US$1,346.00 Beta 0.86 1 Month Change 10.78% 3 Month Change 0.20% 1 Year Change n/a 3 Year Change -14.81% 5 Year Change -17.62% Change since IPO 210.08%
Recent News & Updates
Medtronic plc Announces Chief Financial Officer Changes, Effective March 3, 2025 Jan 22
Medtronic plc Announces Chief Financial Officer Changes Jan 21
Medtronic Announces CMS National Coverage Analysis for Symplicity™ Spyral Renal Denervation System Jan 15
Now 21% undervalued after recent price drop Jan 07
Second quarter dividend of US$0.70 announced Dec 18
Medtronic plc Announces Cash Dividend for Third Quarter of Fiscal Year 2025, Payable on January 10, 2025 Dec 06 See more updates
Medtronic plc Announces Chief Financial Officer Changes, Effective March 3, 2025 Jan 22
Medtronic plc Announces Chief Financial Officer Changes Jan 21
Medtronic Announces CMS National Coverage Analysis for Symplicity™ Spyral Renal Denervation System Jan 15
Now 21% undervalued after recent price drop Jan 07
Second quarter dividend of US$0.70 announced Dec 18
Medtronic plc Announces Cash Dividend for Third Quarter of Fiscal Year 2025, Payable on January 10, 2025 Dec 06
Medtronic plc Receives FDA Clearance for New Inpen App, Pending the Way for Its Smart MDI System Launch with Simplera™? CGM Nov 20
Second quarter 2025 earnings released: EPS: US$0.99 (vs US$0.68 in 2Q 2024) Nov 20
CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter Nov 02
Medtronic plc Announces New, Long-Term Data from Its SPYRAL HTN-ON MED Clinical Trial Oct 29
Medtronic plc Receives FDA Approval of Affera Mapping and Ablation System and Sphere-9 Catheter Oct 25
Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life Oct 04
Medtronic plc Announces the Presentation of Clinical Study Results Sep 30
Upcoming dividend of US$0.70 per share Sep 20
First quarter 2025 earnings released: EPS: US$0.81 (vs US$0.59 in 1Q 2024) Aug 21
Medtronic plc Revises Earnings Guidance for the Fiscal Year 2025 Aug 20
Fourth quarter dividend of US$0.70 announced Aug 19
Medtronic plc Announces Cash Dividend for Second Quarter of Fiscal Year 2025, Payable on October 11, 2024 Aug 16
Medtronic plc, Annual General Meeting, Oct 17, 2024 Aug 12
New minor risk - Earnings quality Jun 29 Medtronic plc Announces Resignation of Karen Parkhill as CFO Jun 27
Upcoming dividend of US$0.70 per share Jun 21
Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024 Jun 06
Full year 2024 earnings released: EPS: US$2.77 (vs US$2.83 in FY 2023) May 26
Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024 May 25
Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints May 18
Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator Apr 27
Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO Apr 11
Insider recently sold Mex$1.2m worth of stock Apr 10
Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women Apr 09
Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World Mar 09
Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024 Mar 08
Third quarter 2024 earnings released: EPS: US$0.99 (vs US$0.92 in 3Q 2023) Feb 21 Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025
Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System Jan 09
Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor Jan 08
Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation Dec 14
Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024 Dec 08
Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024 Nov 22
Second quarter 2024 earnings released: EPS: US$0.68 (vs US$0.32 in 2Q 2023) Nov 22
Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial Oct 25
Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients Sep 20
First quarter 2024 earnings released: EPS: US$0.59 (vs US$0.70 in 1Q 2023) Sep 02
Insider recently sold Mex$14m worth of stock Aug 31 Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System
Medtronic plc Raises Earnings Guidance for 2024 Aug 23
Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023 Aug 18
Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022) Jun 28
Medtronic plc Appoints Greg Lewis as New Director Jun 27
Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users Jun 24
Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer Jun 02 Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023
Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness May 23
Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness May 22 Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors May 13
Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors May 12
Upcoming dividend of US$0.68 per share at 3.5% yield Mar 16
Third quarter 2023 earnings released: EPS: US$0.92 (vs US$1.10 in 3Q 2022) Feb 22 Medtronic plc to Report Q2, 2024 Results on Nov 21, 2023
Medtronic Linq Insertable Cardiac Monitor Detects 10 Times More Atrial Fibrillation in Ischemic Stroke Patients At Three Years Compared to Standard of Care Feb 09 Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units Dec 17
Medtronic Announces First Patient Enrolled in U.S. Clinical Trial for Hugo™ Robotic-Assisted Surgery System Dec 16
Medtronic plc Approves Cash Dividend for the Third Quarter of Fiscal Year 2023, Payable on January 13, 2023 Dec 09 Shareholder Returns MDT N MX Medical Equipment MX Market 7D 0% 0% 0% 1Y n/a 0% 0%
See full shareholder returns
Return vs Market: Insufficient data to determine how MDT N performed against the MX Market .
Price Volatility Is MDT N's price volatile compared to industry and market? MDT N volatility MDT N Average Weekly Movement n/a Medical Equipment Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: MDT N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine MDT N's volatility change over the past year.
About the Company Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
Show more Medtronic plc Fundamentals Summary How do Medtronic's earnings and revenue compare to its market cap? MDT N fundamental statistics Market cap Mex$2.39t Earnings (TTM ) Mex$87.87b Revenue (TTM ) Mex$676.18b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MDT N income statement (TTM ) Revenue US$33.00b Cost of Revenue US$11.42b Gross Profit US$21.58b Other Expenses US$17.29b Earnings US$4.29b
Last Reported Earnings
Oct 25, 2024
Next Earnings Date
Feb 18, 2025
Earnings per share (EPS) 3.34 Gross Margin 65.40% Net Profit Margin 13.00% Debt/Equity Ratio 58.0%
How did MDT N perform over the long term?
See historical performance and comparison Dividends
3.1% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/05 16:15 End of Day Share Price 2025/01/17 00:00 Earnings 2024/10/25 Annual Earnings 2024/04/26
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Medtronic plc is covered by 64 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kadambari Daptardar Accountability Research Corporation Harshit Gupta Accountability Research Corporation David Toung Argus Research Company
Show 61 more analysts 
